KRAS and cancer: Therefore, a sufficiently distinctive macropinocytosis activity between cancer and normal cells is the significant determinant of the rationale for this strategy from the biological perspective, and quantitative analysis of the levels of macropinocytosis in KRAS mt tumor cells and KRAS wt normal cells can help to determine to what extent this KRAS-enhanced macropinocytosis can be harnessed for the delivery of anti-cancer therapeutics.